凯莱英(002821) - 2020 Q4 - 年度财报

Financial Performance - The company's revenue for 2020 was CNY 3,149,689,675.80, representing a 28.04% increase from CNY 2,459,985,533.80 in 2019[14]. - The net profit attributable to shareholders for 2020 was CNY 722,091,360.68, a 30.37% increase compared to CNY 553,863,836.07 in 2019[14]. - The net profit after deducting non-recurring gains and losses was CNY 643,971,039.13, up 31.79% from CNY 488,626,334.69 in 2019[14]. - The company's total assets increased by 90.42% to CNY 7,157,565,543.71 at the end of 2020, compared to CNY 3,758,736,367.43 at the end of 2019[14]. - The basic earnings per share for 2020 was CNY 3.10, reflecting a 28.10% increase from CNY 2.42 in 2019[14]. - The diluted earnings per share for 2020 was CNY 3.08, an increase of 28.33% from CNY 2.40 in 2019[14]. - The net cash flow from operating activities for 2020 was CNY 569,291,589.49, a decrease of 5.26% from CNY 600,867,843.92 in 2019[14]. - The company reported a weighted average return on equity of 18.16% for 2020, down from 19.92% in 2019[14]. - The company received government subsidies amounting to CNY 99,257,315.07 in 2020, compared to CNY 90,483,570.77 in 2019[19]. - The company achieved total revenue of 3.15 billion yuan in 2020, a year-on-year increase of 28.04%, and a quarterly revenue of 1.067 billion yuan in Q4, marking a historical high with a growth of 48.69%[44]. Market Position and Strategy - As a leading global CDMO, the company focuses on technological innovation and commercialization in pharmaceutical processes, providing one-stop CMC services to large and medium-sized pharmaceutical and biotechnology companies[2]. - The company operates under a model that separates marketing authorization from production, allowing for flexibility in manufacturing partnerships[5]. - The company is involved in both clinical and commercial stages of drug development, focusing on innovative drugs and generic drugs[5]. - The company has served over 800 global clients and participated in more than 600 clinical projects, establishing itself as a long-term strategic partner for several multinational pharmaceutical companies[22]. - The company aims to leverage its technological innovations and platform advantages to continuously extend its service offerings and enhance competitive advantages in the CDMO sector[26]. - The company is strategically positioning itself to meet the growing demand in emerging markets, particularly in the Chinese biotechnology sector[43]. Research and Development - The company invested 259 million yuan in R&D, a 34.50% increase year-on-year, representing 8.22% of total revenue, with a total of 279 patent applications filed by the end of the reporting period[55]. - The company has filed a total of 279 patents and has been granted 159 patents, with 27 papers published in leading international journals[37]. - The application rate of continuous reaction technology and biocatalysis in the company's clinical late-stage projects exceeds 30%[31]. - The company has developed a biocatalysis platform with over 1,600 enzymes, including more than 800 proprietary enzymes, to enhance its enzyme-related service capabilities[64]. - The company established a Center of Excellence for Process Science (CEPS) to enhance R&D efficiency and address complex process challenges[58]. Risk Management - The company faces several risks, including the potential withdrawal or large-scale recall of major innovative drugs, operational risks in clinical projects, and risks related to international trade friction and exchange rate fluctuations[2]. - The company emphasizes the importance of risk awareness for investors regarding forward-looking statements and future plans[2]. Corporate Governance - The board of directors and management have confirmed their attendance and participation in the review of the annual report, ensuring governance and accountability[2]. - The company has established a comprehensive corporate governance structure and internal control system to ensure fairness and transparency for all shareholders[155]. - The company has maintained a stable management structure with no significant changes in board members during the reporting period[196]. Environmental Responsibility - The company has maintained compliance with environmental standards, with no instances of exceeding pollutant discharge limits reported[156]. - The company has achieved a VOCs emission concentration of 38.2 mg/m³ at the process exhaust outlet, with total emissions of 26.13 tons, equating to an annual emission of 52.27 tons[159]. - The company has been recognized as a national-level "green factory" by the Ministry of Industry and Information Technology, emphasizing its commitment to environmental protection and sustainable practices[159]. Shareholder Returns - The company proposed a cash dividend of RMB 6.00 per 10 shares for the 2020 fiscal year, which is subject to approval at the annual shareholders' meeting[122]. - The cash dividend for 2020 is fully funded from the company's distributable profits, which totaled RMB 183,406,819.45[124]. - The company has a structured plan for shareholder returns for the years 2020-2022, aligning with its financial strategy[124]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB[129]. - The company plans to continue focusing on the development of innovative drugs and enhancing its CDMO capabilities to capitalize on market growth opportunities[106]. - The company is exploring new product development and technological advancements to stay competitive in the market[199].